782.3000 -7.50 (-0.95%)
NSE Jun 06, 2025 15:31 PM
Volume: 430.4K
 

782.30
-0.95%
ICICI Securities Limited
Strides Pharma Science’s (Strides) Q1FY24 earnings exhibited a healthy beat on margin front. Improved product mix, cost-optimisation initiatives and freight costs led to expansions in gross margin (+880bps YoY) and EBITDA margin (+1,250bps). Management aspires to improve from these levels going ahead. Adjusted for divested businesses, revenue recorded a healthy 11% YoY growth.
Strides Pharma Science Ltd. is trading below its 150 day SMA of 812.2
More from Strides Pharma Sc…
All earning calls
Investor presentations from Strides Pharma Sc…
All investor presentations